Moderna’s melanoma result arrives before the Phase 3 dataset (merck.com)
The announcement concerns an mRNA neoantigen therapy developed with Merck; commenters welcomed the prospect while noting that company statements are not the same as a published dataset.
The tension is healthy rather than cynical: oncology trials fail often, and a clinical headline needs endpoints, duration, and safety detail before it becomes practice.
Sign in to save